Lipocine (LPCN) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 5, 2024, to address key governance and compensation matters.

• Supplement amends the proxy to prohibit repricing of options or stock appreciation rights without shareholder approval.

• Revised Stock and Incentive Plan increases authorized shares from 336,582 to 600,000.

• Board recommends approval of the Revised Plan.

Voting matters and shareholder proposals

• Election of six directors to serve until the next annual meeting.

• Ratification of Tanner LLC as independent auditor for 2024.

• Advisory vote on executive compensation and frequency of future say-on-pay votes.

• Approval sought for amended Stock and Incentive Plan, including share increase and repricing prohibition.

Board of directors and corporate governance

• Board retains authority to amend, suspend, or terminate the Stock and Incentive Plan, subject to shareholder approval for key changes.

• Only independent directors may grant awards to non-employee directors.

• Indemnification provided for board and committee members acting in good faith.